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Aim: Preclinical study of the specific anticancer pharmacological activity of the formulation containing active substance 3,3-di-
indolylmethane (DIM), cod liver oil, polysorbate 80 and α-tocopherol acetate (vitamin E), in vivo in a xenograft animal model 
of LNCaP. Materials and Methods: The DIM, cod liver oil, polysorbate 80 and α-tocopherol acetate (vitamin E) formulation was 
intragastrically administered to BALB/c-nude (nu/nu) mice during 33 days post inoculation at the dose of 133 mg/kg/day. Anti-
tumor activity of the test drug was estimated by the rate of tumor growth inhibition (T/C% — treated versus control), dividing 
the tumor volumes from treatment groups with the control groups. Results: Statistically significant tumor xenograft regressions 
have been shown in group which received the DIM, cod liver oil, polysorbate 80 and α-tocopherol acetate (vitamin E) on the 37th 
day of observation post inoculation. The highest antitumor activity was achieved on the 39th day (T/C = 16,8%). Therapeutic effect 
lasts for 6 days after the end of therapy period. Conclusion: Our findings demonstrate inhibitory effect of the formulation on tumor 
development in the xenograft animal model due to the tumor growth rate reduction.
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3,3-Diindolylmethane (DIM) — one of the most 
prospective compound with antitumor and immu-
nomodulatory properties. A great number of studies 
have revealed that DIM is able to block the multiple 
molecular mechanisms which cause cancer in different 
organs and tissues [1, 2]. In addition to the suppres-
sion of proliferation of transformed (tumor) cells and 
stimulation of their apoptosis, DIM inhibits pathologic 
angiogenesis and reduces the metastatic potential 
of cancer cells by affecting targets which mediate 
processes of cell migration and invasion [3, 4]. It has 
been recently found that DIM is a selective inhibitor 
of certain tumorigenic minor population of non-diffe-
rentiated cancer cells — the so-termed “cancer stem 
cells” [5], which are the main source of recurrence 
and metastasis according to modern ideas. DIM may 
provide some protection against hormone-dependent 
cancers by altering hormone levels, particularly due 
to down-regulation of androgen receptors [2].
The only significant problem in creating DIM-
based anticancer drug is its low bioavailability and, 
as a result, the inability to achieve the therapeutic 
concentrations of active substance in target tissues. 
Generally, DIM exhibits low solubility in physiological 
fluids and has limited ability to permeate through mem-
brane barriers [6, 7]. Based on this, and taking into 
account the uniqueness of the candidate substance 
DIM, the drug DIM, cod liver oil, polysorbate 80 and 
α-tocopherol acetate (vitamin E) was developed. 
Drug formulation is enclosed in a capsule as solution 
containing the active substance — DIM (150 mg), 
as well as organic auxiliary components — cod liver oil, 
polysorbate 80 and α-tocopherol acetate (vitamin E) 
providing high bioavailability and storage stability 
of the drug [8]. It is known that cod liver oil in combina-
tion with polysorbate significantly improves absorption 
in the gastrointestinal tract and distribution in the body, 
and vitamin E increases storage stability [8].
The new drug formulation, created by us on the ba-
sis of modern technological solution, contains DIM 
in a dissolved state, whereby DIM quickly enters 
the blood and the target organs, and reaches concen-
trations which manyfold exceed the concentrations 
of crystalline forms [9]. It was revealed that 5-fold 
higher concentration of DIM was observed in blood 
plasma of rats who received the 2,000-fold lower 
dose of liquid DIM formulation (the DIM, cod liver oil, 
polysorbate 80 and α-tocopherol acetate (vitamin E)) 
compared to crystalline form and non-formulated 
crystalline DIM. We decided to carry out preclinical 
in vivo study of pharmacological activity of the formula-
tion as a therapeutic antitumor agent.
Prostate cancer (PC) is one of the most common 
cancers in the world affecting men. PC in Europe 
is 2nd/3rd cause of cancer deaths, in the USA — 1st. 
PC leads to 29% of fatal causes among patients 
with malignant tumors [10]. In the absence of orga-
nized mass screening programs of early detection 
of PC disease in many cases becomes metastatic 
and incurable.
Modern methods of treating PC — hormone-
dependent cancer — are primarily directed to total 
androgen blockade (androgen deprivation therapy), 
and may involve surgery (radical prostatectomy, 
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 conservative surgery, orchiectomy (rarely)) or hor-
mone therapy using medications.
According to statistics, about 60% of newly diag-
nosed cases of PC aren’t localized, and, consequently, 
most of patients first-time diagnosed with PC, should 
not undergo surgical procedures. Hormone therapy 
is considered the most effective treatment for non-
localized forms of PC, however it allows to control the 
disease only for limited periods of time because hor-
monal resistance inevitably develops [11]. Hormone-
refractory prostate tumors are resistant to treatment, 
highly aggressive and have a poor prognosis [12].
Future prospects of PC treatment involve che-
motherapy combining anti-androgenic effects with 
the targeted inhibition of multiple signaling pathways 
that activate procarcinogens in the prostate gland.
The purpose of this investigation was to study 
specific pharmacological preclinical antitumor activity 
of the new drug — DIM, cod liver oil, polysorbate 80 and 
α-tocopherol acetate (vitamin E) in vivo in a xenograft 
mouse model of PC.
MATERIALS AND METHODS
Reagents. Drug formulation containing DIM, cod 
liver oil, polysorbate 80 and α-tocopherol acetate 
(vitamin E) (ZAO “MiraxBioPharma”, Russia) was pre-
pared according to special patented technology [8]. 
The crystalline DIM (3,3΄-methandiilbis(1H-indol)) (Alexis 
Corporations, Switzerland), cod liver oil and polysor-
bate 80 (Sigma-Aldrich, USA) were used. The solvent 
used in the experiment was a mixture of cod liver oil and 
polysorbate 80 in the same proportions as developed 
drug formulation.
Cell culture. The LNCaP (androgen-sensitive 
human PC cells) was obtained from a collection of tu-
mor strains from the N.N. Blokhin Cancer Research 
Center. All manipulations with cells were performed 
under sterile conditions under a laminar flow hood 
(NuAire, USA). LNCaP cells were maintained in RPMI 
1640 (Gibco, USA) supplemented with 10% FBS (Hy-
Clone, USA), 2 mM L-glutamine and penicillin/strepto-
mycin (100 MU/mL) (Pan Eco, Russia) in an incubator 
at 37 °С and 5% СO2 (Shel Lab, USA). On reaching 
80–90% confluence, the cells were passaged. Cells 
were washed twice with Versen solution, 0.025% 
trypsin (Pan Eco, Russia) was added to the cells and 
incubated for 10 min at 37 °C. After full cell separation 
10 ml of growth medium were added and aggregated 
cells were resuspended. Suspended cells was trans-
ferred for the following cells inoculation.
Animals. LNCaP cell inoculation. Study was car-
ried out using 60 immunodeficient male Balb/c-nude 
(nu/nu) mice (4–5 weeks) which were purchased from 
Charles River GmbH (Germany). The length of qu-
arantine was 14 days. During this time daily inspections 
of behavior and general condition of each animal were 
undertaken.
The animals were housed in standard cages 
(Techniplast, Italy), connected to the air conditioning unit 
TouchSLIM Plus® (Techniplast, Italy), 4–8 mice/cage. 
The following microclimate parameters were maintained: 
light conditions: 12 h — light, 12 h — dark; air tempera-
ture 24–26 °С; relative humidity 30±70%; air exchange 
8–10 room volumes per hour. The animals had free ac-
cess to distilled water and food (PMI LabDiet® 5K67). 
Food and water were pre-sterilized (autoclaving).
All animals were inoculated with LNCaP cells sub-
cutaneously along the spine (in left scapular region) 
after adaptation period. LNCaP cell line inoculation 
was carried out by injection of 0.2 ml of tumor suspen-
sion in sterile solution of PBS (Sigma, USA), containing 
5 mln cells (25•106 cells/ml). All manipulations with 
animals were approved by the local Animal Care and 
Use Committee.
Treatment protocols. At 3 days after LNCaP cell 
inoculation, animals which met criteria for inclusion 
were randomized and individually labeled. Two groups 
of animals were formed: control and experimental 
(animals treated with the formulation) — 30 mice 
each. In experimental group animals were adminis-
tered with the formulation twice daily (in the morning 
and evening) with an interval of 8–9 h intragastrically 
at a dose of 133 mg/kg/day (per DIM) by atraumatic 
gavage for 33 days. The control group treated with 
the same amount of solvent (cod liver oil + polysorbate) 
on the same schedule. Tumor growth was monitored 
for a further 6 days after the end treatment period. 
In the days of administration of drug/solvent animals 
were inspected at a specified time prior to and two 
hours after administration.
Euthanasia was carried out by CO2-inhalation.
Assessment of antitumor activity. Tumor vo lume 
measurements began at the initiation of tumor growth 
and continued twice a week. Tumor volumes were 
measured with caliper and were calculated by the fol-
lowing formula (Vt): 
Vt (mm3) = L • W2/2, 
where L — the longest  tumor diameter, 
W — the shortest tumor diameter.
Antitumor activity of the DIM formulation was esti-
mated by tumor growth inhibition ratio (Т/C%), where 
T and C represent the means of the tumor volumes 
of the control (VC) and treatment mice (VI) in each ex-
periment day (VI/VC • 100%). Another value of inhibition 
ratio (D%) was reckoned by the formula: 
D% = (VC−VI)/VC • 100%.
Behavior and general condition of animals have 
been registered both in experimental and control 
groups. Animals were weighted 2–3 times a week.
Statistical analysis. Statistical differences in tu-
mor growth inhibition ratio (Т/C%) between treated 
and untreated groups were determined using Stu-
dent’s t-test by means of GraphPad Prism 5 software. 
Differences were statistically significant at p < 0.05.
RESULTS AND DISCUSSION
Study of the antitumor activity of the formula-
tion in subcutaneous LNCaP xenografts. The effect 
of the DIM formulation on tumor growth dynamics 
was evaluated by measuring changes in tumor size 
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in response to treatment in immunodeficient mice 
Balb/c-nude (nu/u) subcutaneously implanted with 
human PC line LNCaP. Figure shows the average tumor 
sizes in control and experimental groups of animals 
in each study day.
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Figure. Dynamics of tumor growth in PC3 xenograft mouse model 
in experimental (after intragastrically administration of the DIM for-
mulation for 33 days at a dose of 130 mg/kg/day) and control groups
The average tumor volumes of the treated 
mice were not significantly different (ns) from that 
of the control group till the 33-rd day post tumor cell 
inoculation. Subsequently, however, the antitumor 
effect of injected drug has become more evident. Sta-
tistically significant size reduction of the tumors treated 
with the formulation compared with the control tumors 
have registered since 37 day. As a result within 42 days 
post inoculation the average volume of full-grown xe-
nograft tumors in control group reached ~ 600 mm3, 
by comparison only ~100 mm3 in experimental group 
(animals treated with the formulation). Therapeutic ef-
fect lasts for 6 days till study ends after the cessation 
of the formulation administration (36th day after cell 
inoculation). We suggest that this is result of stable 
positive changes, caused by multiple targeted action 
of the active substance on the molecular intracellular 
mechanisms that mediate tumor growth.
According to the data, the highest antitumor effect 
of the DIM formulation was observed on the 39th day 
of experiment (37th day of observation post inocula-
tion), when the T/C% ratio, which was calculated by di-
viding the average tumor volumes of experimental ani-
mals by the control values, reached 16.8%. In the same 
day of the experiment the value of inhibition ratio (D%) 
was 83.2%. The values of these parameters remained 
unchanged until the end of experiment.
Besides, we’ve registered dynamics of animals’ 
weight. It was shown that animals in both groups had 
weight loss after the drug/solvent administration, 
 however weight and general condition of animals be-
came stable through about a week.
Thus the average volume of xenograft tumors in ex-
perimental group which was treated with the formula-
tion was 6-fold less than in group treated with original 
DIM and T/C ratio reached 16.8% on day 42.
It should be noted that anticancer activity of crys-
talline DIM, and bioresponse-DIM (BR-DIM) formula-
tion (“BioResponse” LLC, USA), which contains DIM 
combined with pegylated vitamin E and phosphatidyl 
choline, has been successfully studied by different 
authors in xenograft model of PC [2, 13–15], and 
other cancers [3, 16–19]. However, bioavailability 
of DIM in  BR-DIM formulation compared with crystal-
line DIM was enhanced only in 1,5- to 2-fold, which 
demon strate that administration of BR-DIM formu-
lation (per os) doesn’t ensure peak concentrations 
of the active substance (DIM) and, consequently, de-
sired therapeutic effect. This could help to explain why 
no significant clinical effect was achieved with  BR-DIM 
formulation in treatment of cervical dysplasia [20].
However, animal in vivo experiments revealed that 
crystalline DIM and BR-DIM formulation — by various 
routes of administration — demonstrate significant 
dose-dependent antitumor effect. They induced 
a reduction in tumor volume which was established 
by implantation of PC3 cells, and/or reduce the amount 
of newly formed metastases. According to the study 
in a SKOV-3 xenograft tumor model of ovarian cancer 
Т/C ratio was 47.2%, in other study this value was 
51.63% (PC3 xenograft tumor model of PC) (Т/C values 
were calculated according to the original experimental 
data reported in these publications).
Our findings confirm inhibitory effect of the new for-
mulation containing DIM, cod liver oil, polysorbate 80 and 
α-tocopherol acetate (vitamin E) on tumor development 
in the xenograft animal model and complement previ-
ously obtained experimental data.
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